 |
ondansetron inhalation powder |
|---|---|
| Trade Name | |
| Orphan Indication | Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) |
| USA Market Approval | USA |
| USA Designation Date | 2015-10-14 00:00:00 |
| Sponsor | Luxena Pharmaceuticals, Inc.;1400 Coleman Avenue, Suite D27;Santa Clara, California, 95050 |
